Network origin in Claudia D'Augusta first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
21
| Holding Company | Medical Specialties | 21 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.
11
| Private Company | Investment Managers | 11 |
| Public Company | Pharmaceuticals: Major | 7 | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.
5
| Subsidiary | Pharmaceuticals: Generic | 5 |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
2
| Extinct | Biotechnology | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Claudia D'Augusta via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Université Catholique de Louvain | College/University | Chairman Graduate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Director/Board Member Doctorate Degree | |
| University of Barcelona | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman Director/Board Member | |
| Ghent University | College/University | Doctorate Degree Doctorate Degree | |
| Instituto de Empresa SL | College/University | Masters Business Admin Graduate Degree | |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Operating Officer Founder | |
GlaxoSmithKline Services Unlimited
 GlaxoSmithKline Services Unlimited Pharmaceuticals: MajorHealth Technology Glaxosmithkline Services Unlimited Ltd. develops, manufactures and markets pharmaceutical products. The company was incorporated on March 23, 1972 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Gri-Cel SA
 Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. | Financial Conglomerates | Chief Executive Officer Chief Operating Officer | |
Novavax AB
 Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Pharmaceuticals: Generic | Chief Executive Officer Chief Executive Officer | |
| Antisoma Research Ltd. | Corporate Officer/Principal General Counsel | ||
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Universitat Autònoma de Barcelona | College/University | Graduate Degree Undergraduate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
 Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Corporate Officer/Principal Director/Board Member | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman | |
OncoDNA SA
 OncoDNA SA Medical/Nursing ServicesHealth Services OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium. | Medical/Nursing Services | Chairman Chief Executive Officer | |
| Vlerick Leuven Gent Management School | College/University | Director/Board Member Masters Business Admin | |
| London Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ABLYNX | Biotechnology | Director/Board Member Chairman | |
| Universidad Complutense de Madrid | College/University | Doctorate Degree Graduate Degree | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Chief Executive Officer | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| The University of Manchester | College/University | Undergraduate Degree Doctorate Degree | |
| ARCUS BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Staines Upon Thames, UK and was founded in 2015. | Pharmaceuticals: Major | Director/Board Member | |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Chairman | |
| University of Hertfordshire | College/University | Undergraduate Degree | |
| VAXCYTE, INC. | Biotechnology | Chairman | |
Abingworth Management, Inc.
 Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Investment Managers | Consultant / Advisor | |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| REDX PHARMA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The University of Law Ltd. | College/University | Graduate Degree | |
| STANDARD BIOTOOLS INC. | Medical Specialties | Chairman |
Statistics
International
| Spain | 12 |
| Belgium | 11 |
| United Kingdom | 11 |
| United States | 8 |
| Switzerland | 5 |
Sectoral
| Health Technology | 29 |
| Consumer Services | 15 |
| Commercial Services | 4 |
| Finance | 3 |
| Health Services | 2 |
Operational
| Director/Board Member | 249 |
| Chairman | 102 |
| Corporate Officer/Principal | 96 |
| Independent Dir/Board Member | 52 |
| Chief Executive Officer | 39 |
Most connected contacts
| Insiders | |
|---|---|
| Koenraad Debackere | 48 |
| Simon Cartmell | 39 |
| Baron Jean Stéphenne | 36 |
| Russell Greig | 31 |
| Mounia Chaoui-Roulleau | 27 |
| Peter Andersen | 26 |
| John Berriman | 24 |
| Sven Arne Andréasson | 24 |
| Paul Harper | 20 |
| Pamela Klein | 19 |
| Eduardo Bravo Fernández de Araoz | 19 |
| Gil Beyen | 18 |
| Joël Jean-Mairet | 17 |
| Nico Vandervelpen | 17 |
| Marie Paule Richard | 15 |
- Stock Market
- Insiders
- Claudia D'Augusta
- Company connections
